Latest Capital Management News

Regis Resources has reported a record quarterly cash and bullion build of $255 million, lifting its total cash and bullion reserves to $930 million, alongside solid gold production in the December 2025 quarter.

Sports Entertainment Group has completed its staged divestment of the Perth Wildcats, selling its remaining 30.6% stake for $12 million and concluding a $39.5 million exit. The move marks a strategic shift as SEG eyes new capital management opportunities.

WAM Active Limited has reported its strongest investment performance since inception, with a 41.4% return over 12 months and increased fully franked dividends, signalling confidence in its dynamic portfolio strategy heading into 2026.

AVA Risk Group has locked in a strategic investment of up to A$12.6 million from US-based Hale Capital, aiming to boost its footprint in the lucrative US critical infrastructure market. The deal includes convertible notes and warrants priced at an 81% premium, alongside a new board appointment.

US Masters Residential Property Group has amended its term loan facility, increasing the interest rate and extending the maturity date to enhance capital management flexibility.

Australis Oil and Gas has completed a pivotal financing transaction with EQV Partners, transferring 90% interest in its producing wells and clearing its debt with Macquarie Bank. This move reshapes its operational and financial landscape as it prepares for upcoming drilling activities.

Mesoblast has refinanced its senior debt with a new US$125 million, five-year credit facility that lowers borrowing costs and preserves key assets, positioning the company for strategic growth.

Argo Investments Limited has announced the renewal of its on-market buy-back facility, allowing the company to repurchase up to 37 million ordinary shares throughout 2026 as part of its capital management strategy.

Westpac Banking Corporation has announced a fully franked distribution of AUD 1.1789 per Westpac Capital Notes 10 for the quarter ending March 2026, reflecting a 4.78% annualised yield based on current market rates.

Scentre Group has sold a 19.9% stake in Westfield Sydney to Australian Retirement Trust for $864 million, reinforcing its strategy of capital recycling through joint ventures.

Next Science has obtained a crucial ASX waiver allowing it to return surplus capital to shareholders following its $50 million asset sale, despite expected share price declines below 20 cents.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.